Close

Pulmatrix (PULM) Receives Patents on Inhaled Drug Delivery Technology and COPD Drug

September 20, 2017 9:42 AM EDT Send to a Friend
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login